CTAD 2022 | Prioritizing the mechanistic understanding of AD to improve treatments

Jared C. Roach, MD, PhD, Institute for Systems Biology, Seattle, WA, explains the importance and potential of using systems biology based multimodal trial approaches for the personalization of interventions in Alzheimer’s disease (AD). Past approaches to treating AD have been based on aggregate knowledge. However, if the mechanistic understanding of AD is prioritized, a more complete picture of AD will be formed, and treatment interventions can be more effectively personalized. This interview took place at the Clinical Trials on Alzheimer’s Disease Congress 2022 in San Francisco.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.